ProQR Therapeutics N.V.
PRQR$199M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLEIDEN150 employees
ProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
PRQR News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
sepofarsen
Leber Congenital Amaurosis 10
QR-1123
Autosomal Dominant Retinitis Pigmentosa
QR-421a
Retinitis Pigmentosa
QR-010
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sepofarsen | Phase 3 | Leber Congenital Amaurosis 10 | - | - |
QR-1123 | Phase 2 | Autosomal Dominant Retinitis Pigmentosa | - | - |
QR-421a | Phase 2 | Retinitis Pigmentosa | - | - |
QR-010 | Phase 2 | Cystic Fibrosis | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply